Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959133 | 0.83 | KDM4E (0.38) | KDM4ESLC6A4SLC6A2SLC6A3CYP2A6 | |
| SCHEMBL2970149 | 0.82 | KIF11 (0.32) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2959349 | 0.81 | KDM4E (0.41) | KDM4ESLC6A4SLC6A2SLC6A3CYP2A6 | |
| SCHEMBL2975187 | 0.81 | CYP2A6 (0.36) | KDM4ESLC6A4SLC6A2SLC6A3CYP2A6 | |
| SCHEMBL2972005 | 0.79 | ALDH1A1 (0.30) | — | |
| SCHEMBL2959817 | 0.78 | KDM4E (0.38) | KDM4ESLC6A4SLC6A2SLC6A3CYP2A6 | |
| SCHEMBL2962745 | 0.77 | CYP2A6 (0.38) | SLC6A4SLC6A2SLC6A3CYP2A6DRD2 | |
| SCHEMBL2972006 | 0.76 | PBRM1 (0.33) | HTR2C | |
| SCHEMBL2973621 | 0.75 | KDM4E (0.38) | KDM4ESLC6A4SLC6A2SLC6A3CYP2A6 | |
| SCHEMBL2973809 | 0.75 | KDM4E (0.38) | KDM4ESLC6A4SLC6A2SLC6A3CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2006065809-A2 | HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | KDM4E 2177/4885SLC6A4 2785/4885SLC6A2 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.